IP Library Granted Patent US 10,087,494
Granted Patent B2
US 10,087,494 · App. 14/569,338 · Granted Oct 2, 2018

Assay for detection of human parvovirus nucleic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,087,494
App. No.
14/569,338
Granted
Oct 2, 2018
Kind
B2
Abstract

Nucleic acid oligomers specific for human parvovirus genomic DNA are disclosed. An assay for amplifying and detecting human parvovirus genotypes 1, 2 and 3 nucleic acid in biological specimens is disclosed. Compositions for amplifying and detecting the presence of human parvovirus genotypes 1, 2 and 3 genomic DNA in human biological specimens are disclosed.

Claims (22)

1. An amplification oligomer combination for amplifying human parvovirus genotypes 1, 2, and 3, the oligomer combination comprising:

a) at least one primer oligomer member comprising a target binding sequence that is SEQ ID NO:48 or SEQ ID NO:50;

b) a first promoter-based oligomer member comprising a sequence that is SEQ ID NO:73; and

c) a second promoter-based oligomer member comprising a sequence that is SEQ ID NO:78.

2. An amplification oligomer combination for amplifying human parvovirus genotypes 1, 2, and 3, the oligomer combination comprising at least one primer oligomer member and at least one promoter-based oligomer member, wherein the at least one primer oligomer member and the at least one promoter-based oligomer member hybridize to opposing strands of a human parvovirus genotype 1, 2 or 3 nucleic acid or amplicon thereof for transcription mediated amplification of the target nucleic acid or amplicon thereof between the hybridized primer and promoter-based oligomer members, wherein

A) the at least one promoter-based oligomer member is a first promoter-based oligomer member that is SEQ ID NO:76 and a second promoter-based oligomer member that is SEQ ID NO:81;

B) the at least one promoter-based oligomer member is selected from the group consisting of SEQ ID NOS:58, 63, 67, 68, 73, 78, 82, and combinations thereof;

C) the at least one primer oligomer member is SEQ ID NO:50 and the at least one promoter-based oligomer member is a first promoter-based oligomer member that is SEQ ID NO:73 and a second promoter-based oligomer member that is SEQ ID NO:78; or

D) the at least one primer oligomer member is SEQ ID NO:47 and the at least one promoter-based oligomer member is selected from the group consisting of SEQ ID NOs:73, 76, 78, 81 and combinations thereof.

3. The amplification oligomer combination of claim 1 , wherein the at least one primer oligomer member comprises the target-binding sequence that is SEQ ID NO:50.

4. The amplification oligomer combination of claim 1 , wherein the at least one primer oligomer member comprises the target-binding sequence that is SEQ ID NO:48.

5. The amplification oligomer combination of claim 1 , wherein the at least one primer oligomer member is SEQ ID NO:47.

6. The amplification oligomer combination of claim 1 , wherein the at least one primer member is selected from the group consisting of SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50 and combinations thereof.

7. A reaction mixture for performing a transcription mediated amplification reaction, wherein the reaction mixture comprises:

a) an amplification oligomer combination comprising:

i) at least one primer oligomer member comprising a target binding sequence that is SEQ ID NO:48 or SEQ ID NO:50;

ii) a first promoter-based oligomer member comprising a sequence that is SEQ ID NO:73; and

iii) a second promoter-based oligomer member comprising a sequence that is SEQ ID NO:78;

and

b) an enzyme comprising an activity selected from the group consisting of reverse transcriptase activity, RNA polymerase activity, and RNase H activity.

8. The reaction mixture of claim 7 , wherein the enzyme comprises reverse transcriptase activity and RNase H activity.

9. The amplification oligomer combination of claim 2 , wherein the at least one promoter-based oligomer member comprises a blocking moiety at its 3′ end.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 14, 2019
From: HOLOGIC, INC.; CYNOSURE, LLC; CYTYC CORPORATION; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 050719/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2018
From: CARRICK, JAMES M.
To: GEN-PROBE INCORPORATED
Reel/Frame 045957/0389 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →